Bone responsiveness to parathyroid hormone in normal and osteoporotic postmenopausal women
- PMID: 2793989
- DOI: 10.1210/jcem-69-5-1024
Bone responsiveness to parathyroid hormone in normal and osteoporotic postmenopausal women
Abstract
Increased bone loss in estrogen-deficient normal and osteoporotic postmenopausal women may be due mainly to increased sensitivity of bone-resorbing cells to circulating PTH, but this is supported only by indirect data. Therefore, we tested the responsiveness of bone to PTH directly by using a 3-day iv infusion of bovine PTH-(1-34) at 400 U/day in 9 normal premenopausal women, 10 normal postmenopausal women, and 12 osteoporotic postmenopausal women. Serum calcium and urinary hydroxyproline concentrations increased (P less than 0.001) over baseline values during infusion, but the mean increases in both variables did not differ among groups. The data do not support the hypothesis that estrogen deficiency increases the sensitivity of bone to PTH or that the sensitivity in osteoporotic women is greater than that in normal postmenopausal women. Within the constraints imposed by the method of testing, we conclude that the additional bone resorption induced by menopause and by osteoporosis may be due to mechanisms that are not due to enhanced responsiveness of bone to PTH.
Similar articles
-
Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis.J Bone Miner Res. 2008 May;23(5):721-9. doi: 10.1359/jbmr.071117. J Bone Miner Res. 2008. PMID: 18052753
-
Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement therapy?J Bone Miner Res. 1997 Jan;12(1):78-88. doi: 10.1359/jbmr.1997.12.1.78. J Bone Miner Res. 1997. PMID: 9240729
-
A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.J Clin Endocrinol Metab. 1997 Feb;82(2):620-8. doi: 10.1210/jcem.82.2.3762. J Clin Endocrinol Metab. 1997. PMID: 9024265 Clinical Trial.
-
[Bone and hormones. Effects of parathyroid hormone on the bone].Presse Med. 1999 Mar 13;28(10):547-53. Presse Med. 1999. PMID: 10209548 Review. French.
-
What can we learn from bone biology for the treatment for osteoporosis?Osteoporos Int. 1999;9 Suppl 2:S40-7. doi: 10.1007/pl00004160. Osteoporos Int. 1999. PMID: 10525725 Review. No abstract available.
Cited by
-
Relationship between serum intact parathyroid hormone concentrations and bone remodeling in type I osteoporosis: evidence that skeletal sensitivity is increased.Osteoporos Int. 1990 Oct;1(1):14-22. doi: 10.1007/BF01880411. Osteoporos Int. 1990. PMID: 2133635
-
Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis.J Clin Endocrinol Metab. 2009 Aug;94(8):2915-21. doi: 10.1210/jc.2008-2630. Epub 2009 May 12. J Clin Endocrinol Metab. 2009. PMID: 19435827 Free PMC article.
-
Overview of osteoporosis.West J Med. 1991 Jan;154(1):63-77. West J Med. 1991. PMID: 2024511 Free PMC article. Review.
-
Bone density parathyroid hormone and 25-hydroxyvitamin D concentrations in middle aged women.BMJ. 1992 Aug 1;305(6848):273-7. doi: 10.1136/bmj.305.6848.273. BMJ. 1992. PMID: 1392857 Free PMC article.
-
Oxidation of recombinant human parathyroid hormone: effect of oxidized position on the biological activity.Pharm Res. 1995 Dec;12(12):2049-52. doi: 10.1023/a:1016281031373. Pharm Res. 1995. PMID: 8786987
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical